Caladrius Biosciences (NASDAQ: CLBS) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.
Earnings and Valuation
This table compares Caladrius Biosciences and Global Blood Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Global Blood Therapeutics||N/A||N/A||-$95.43 million||($2.47)||-13.34|
Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Caladrius Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
6.5% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 86.1% of Global Blood Therapeutics shares are owned by institutional investors. 13.1% of Caladrius Biosciences shares are owned by insiders. Comparatively, 5.3% of Global Blood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Caladrius Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 4.21, meaning that its stock price is 321% more volatile than the S&P 500.
This table compares Caladrius Biosciences and Global Blood Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-38.92%||-36.49%|
This is a summary of current ratings for Caladrius Biosciences and Global Blood Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||0||11||0||3.00|
Caladrius Biosciences currently has a consensus price target of $6.75, suggesting a potential upside of 89.61%. Global Blood Therapeutics has a consensus price target of $55.73, suggesting a potential upside of 69.13%. Given Caladrius Biosciences’ higher possible upside, equities research analysts plainly believe Caladrius Biosciences is more favorable than Global Blood Therapeutics.
Global Blood Therapeutics beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.